US Market Report for Ankylosing Spondylitis Immunology Drugs 2018 - Unit Sales, ASPs, Market Value & Growth Trends

General Report Contents

Treatment options for the AS include medication, exercise, physical therapy and others. In severe cases posture correcting surgery may also be an option. The medication treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, and aspirin. If NSAIDs alone do not control inflammation, it may require an injection of corticosteroids directly into the affected joints to bring quick but temporary relief. An injection may be given to the sacroiliac, hip, knee joint, but it is not given in the spine.

Key Topics Covered:

Executive Summary

1. Version History

2. 9-Step Methodology

3. Mechanism of Action
3.1 Introduction
3.1.1 Tumor Necrosis Factor (Tnf)
3.1.2 B-Cell Inhibitors
3.1.3 Interleukin Inhibitors
3.1.4 Janus Kinase Inhibitors
3.1.5 Co-Stimulation Modulators

4. Product Assessment
4.1 Key Marketed Products
4.1.1 Abatacept (Orencia)
4.1.1.1 Future Developments
4.1.1.2 Currently Marketed Products By Company
4.1.2 Adalimumab (Humira)
4.1.2.1 Future Developments
4.1.2.2 Currently Marketed Products By Company
4.1.3 Certolizumab Pegol (Cimzia)
4.1.3.1 Future Developments
4.1.3.2 Currently Marketed Products By Company
4.1.4 Etanercept (Enbrel, Benepali)
4.1.4.1 Future Developments
4.1.4.2 Currently Marketed Products By Company
4.1.5 Golimumab (Simponi)
4.1.5.1 Future Developments
4.1.5.2 Currently Marketed Products By Company
4.1.6 Infliximab (Remicade, Inflectra, Remsima, Flixabi, Renflexis)
4.1.6.1 Future Developments
4.1.6.2 Currently Marketed Products By Company
4.1.7 Natalizumab (Tysabri)
4.1.7.1 Currently Marketed Products By Company
4.1.8 Rituximab (Rituxan, Mabthera, Rixathon, Truxima)
4.1.8.1 Future Developments
4.1.8.2 Currently Marketed Products By Company
4.1.9 Tocilizumab (Actemra/Roactemra)
4.1.9.1 Currently Marketed Products By Company
4.1.10 Tofacitinib (Xeljanz)
4.1.10.1 Future Developments
4.1.10.2 Currently Marketed Products By Company
4.1.11 Ustekinumab (Stelara)
4.1.11.1 Future Developments
4.1.11.2 Currently Marketed Products By Company
4.1.12 Vedolizumab (Entyvio)
4.1.12.1 Currently Marketed Products By Company
4.2 Key Products in Pipeline
4.2.1 Barcitinb (Olumiant)
4.2.2 Guselkumab (Tremfya)
4.2.3 Cobitolimod (Kappaproct)
4.2.4 Mavrilimumab
4.2.5 Sirukumab
4.2.6 Vobarilizumab
4.3 Products in Development By Core Companies
4.4 Clinical Trial By Disease
4.4.1 Rheumatoid Arthritis
4.4.1.1 Study Completion Date: 2017
4.4.1.2 Study Completion Date: 2016
4.4.2 Crohn'S Disease (Cd)
4.4.2.1 Study Completion Date: 2017
4.4.2.2 Study Completion Date: 2016
4.4.2.3 Study Completion Date: 2015
4.4.3 Ankylosing Spondylitis (As)
4.4.3.1 Study Completion Date: 2017
4.4.3.2 Study Completion Date: 2016
4.4.3.3 Study Completion Date: 2015
4.4.4 Psoriasis (Ps)
4.4.4.1 Study Completion Date: 2017
4.4.4.2 Study Completion Date: 2016
4.4.5 Ulcerative Colitis (Uc)
4.4.5.1 Study Completion Date: 2016
4.4.5.2 Study Completion Date: 2015

5. Country Profile
5.1 United States
5.1.1 Population And Demographics
5.1.2 Treatment Size Analysis for 2017
5.1.3 Drug Cost Analysis

6. Ankylosing Spondylitis Market
6.1 Introduction
6.1.1 Causes And Disease Progression
6.1.2 Diagnosis And Treatment Options
6.1.3 Symptoms And Complications
6.1.4 Epidemiology
6.2 Market Overview
6.3 Trend Analysis
6.4 Competitive Analysis

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/d4gb47/us_market_report

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716